Advertisement
Advertisement
U.S. Markets open in 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6000-0.9100 (-25.93%)
At close: 04:00PM EST
2.6100 +0.01 (+0.38%)
Pre-Market: 07:21AM EST
Advertisement

Acorda Therapeutics, Inc.

420 Saw Mill River Road
Ardsley, NY 10502
United States
914 347 4300
http://www.acorda.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees167

Key Executives

NameTitlePayExercisedYear Born
Dr. Ron Cohen M.D.Founder, CEO, Pres & Director1.5MN/A1956
Ms. Lauren M. SabellaChief Operating Officer758.61kN/A1961
Dr. Burkhard BlankChief Medical Officer and Head of R&D860.59kN/A1955
Mr. Robert MoralesInterim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & ControllerN/AN/A1967
Ms. Felicia VonellaVP of Investor RelationsN/AN/AN/A
Ms. Denise J. DucaExec. VP of HRN/AN/AN/A
Dr. Andrew R. BlightChief Scientific Officer EmeritusN/AN/A1951
Mr. Kerry M. ClemChief Commercial OfficerN/AN/AN/A
Mr. Andrew Mayer J.D.Sr. VP, Deputy Gen. Counsel & Corp. Sec.N/AN/AN/A
Dr. Wise Young M.D., Ph.D.Special Scientific AdvisorN/AN/A1950
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Corporate Governance

Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement